Dave is a principal at EY with more than 25 years of experience in strategy, innovation and management consulting. His primary focus is helping organizations create the capacity to grow through strategic planning, performance improvement and innovation in the pharmaceutical, biotechnology, OTC and medical device sectors. He has led numerous growth and innovation initiatives for large, mid-market and start-up companies, including short- and long-term strategic planning, internal venturing, innovation centers, culture creation, global product launch, clinical operations transformation and high performance team development. He currently serves as the Northeast Life Sciences Market Segment leader, where he is responsible for ensuring exceptional client service to all of the firm’s pharma, biotech and medtech clients from Washington, D.C. to Boston. The Northeast Life Sciences practice has consistently ranked among the growth leaders in the Northeast and the global firm. Prior to this role, he served as the Global Client Service Partner for Johnson & Johnson (J&J). In 2014, J&J achieved the milestone of having full service line integration at a significant scale. While serving J&J, he led the creation of J&J’s Janssen Healthcare Innovation unit (JHI). This entailed the development of JHI’s business model innovation strategy, creation of commercial trial portfolio management processes and global organizational design and development. Today, JHI remains a critical piece of J&J’s overall innovation prowess. He is a member of EY’s Global Life Sciences leadership team. In this capacity, he contributes to the development of EY thought leadership, such as the Pharma 3.0 series.
Prior to joining EY, Dave was VP of Strategy at Cambrex Corporation (Cambrex), where he developed the strategy to transform Cambrex from a contract manufacturing organization to a specialty therapeutics company and, prior to that, he served as the Global Aesthetics Franchise leader for Aventis Dermatology, where he restructured the global marketing strategy and led the US launch for Sculptra. Dave was a VP at CapGemini, responsible for the Aventis NA relationship. In this role, he worked closely with the Aventis NA leadership team post-merger and helped the team create and implement a growth strategy aimed at doubling the business in four years, while building the culture from scratch. His consulting assignments for Aventis NA ranged from creating captive innovation capabilities to launching Lantus, a first to market basal insulin block buster product, to facilitating the North American Leadership Team to becoming a high performance team. Prior to CapGemini, Dave was a successful entrepreneur in the boutique strategy and innovation consulting firm, Idea Connection Systems (ICS). While leading the growth of ICS, he served the life sciences, government, energy, automotive and manufacturing sectors. He worked with clients on assignments, ranging from developing the United States Air Force 25-year strategic plan, to installing Innovation Centers for GM to reengineering Exxon’s R&D processes. He also conducted and published research on cognitive creative styles that underpin the innovation process. Dave began his career at Amoco Chemical as a chemist, where he was assigned two patents for carbon hydrogen bond activation. He also started Amoco Chemical’s internal venturing program.